Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus
- 1 May 2002
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 136 (2) , 296-302
- https://doi.org/10.1038/sj.bjp.0704702
Abstract
1. We previously reported a presynaptic facilitatory action of A(2A) receptors on GABAergic synaptic transmission in the rat globus pallidus (GP). In the present study we identify the intracellular signalling mechanisms responsible for this facilitatory action of A(2A) receptors, using biochemical and patch-clamp methods in rat GP slices. 2. The adenosine A(2A) receptor selective agonist CGS21680 (1, 10 microM) and the adenylyl cyclase activator forskolin (1, 10 microM) both significantly increased cyclic AMP accumulation in GP slices. The CGS21680 (1 microM)-mediated increase in cyclic AMP was inhibited by the A(2A) receptor selective antagonist KF17837 (10 microM). 3. In an analysis of miniature inhibitory postsynaptic currents (mIPSCs), forskolin (10 microM) increased the mIPSC frequency without affecting their amplitude distribution, a result similar to that previously reported with CGS21680. 4. The adenylyl cyclase inhibitor 9-(tetrahydro-2-furanyl)-9H-purin-6-amine (SQ22,536, 300 microM) abolished the CGS21680-induced enhancement in the frequency of mIPSCs. 5. H-89 (10 microM), a selective inhibitor for cyclic AMP-dependent protein kinase (PKA), blocked the CGS21680-induced enhancement of the mIPSC frequency. 6. The calcium channel blocker CdCl(2) (100 microM) did not prevent CGS21680 from increasing the frequency of mIPSCs. 7. These results indicate that A(2A) receptor-mediated potentiation of mIPSCs in the GP involves the sequential activation of the A(2A) receptor, adenylyl cyclase, and then PKA, and that this facilitatory modulation could occur independently of presynaptic Ca(2+) influx.Keywords
This publication has 39 references indexed in Scilit:
- New Aspects of Physiological and Pathophysiological Functions of Adenosine A2AReceptor in Basal GangliaBioscience, Biotechnology, and Biochemistry, 2001
- Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 1997
- Adenosine A2A antagonists with potent anti-cataleptic activityBioorganic & Medicinal Chemistry Letters, 1997
- Direct Modulation of the Secretory Machinery Underlies PKA-Dependent Synaptic Facilitation in Hippocampal NeuronsNeuron, 1996
- Basal ganglia and movement disorders: an updateTrends in Neurosciences, 1996
- Basal ganglia and movement disorders: an updateTrends in Neurosciences, 1996
- Dual Signalling by the Adenosine A2a Receptor Involves Activation of Both N‐ and P‐Type Calcium Channels by Different G Proteins and Protein Kinases in the Same Striatal Nerve TerminalsJournal of Neurochemistry, 1996
- Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitryBrain Research Reviews, 1995
- KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine) a potent and selective adenosine A2 receptor antagonistEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989